SHI Pharmaceutical Group: ALMB-0166 approved for clinical trials in China for the treatment of Parkinson's disease.

The notice from Shi Pharmaceuticals Group announces that ALMB-0166, developed by the group, has been approved by the National Medical Products Administration of the People's Republic of China for phase II clinical trials in China to evaluate its effectiveness in patients with Parkinson's disease. ALMB-0166 is a novel humanized monoclonal antibody inhibitor targeting the novel Connexin 43 cellular membrane protein, developed by the group's subsidiary Ala Mab Therapeutics Inc., for the treatment of neurological diseases such as Parkinson's disease, acute ischemic stroke, and acute spinal cord injury.